| Bioactivity | CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma[1]. |
| Invitro | CCG-232601 inhibits SRE.L activity with an IC50 of 0.55 µM[1]. |
| In Vivo | CCG-232601 (50 mg/kg; i.g.; intracutaneous injections of bleomycin; daily for 14 days) inhibits bleomycin-induced skin fibrosis in mice[1]. |
| Name | CCG-232601 |
| CAS | 1922099-21-5 |
| Formula | C24H20ClF2N3O2 |
| Molar Mass | 455.88 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hutchings KM, et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749. |
CCG-232601
CAS: 1922099-21-5 F: C24H20ClF2N3O2 W: 455.88
CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.